Efficacy and safety of tarenflurbil, a selective a beta 42-lowering agent, in Alzheimer's disease (AD): A phase 2 trial of up to 24 months of treatment - Black, S; Wilcock, G; Zavitz, K; Hendrix, S; Swabb, E (2008)